FDA asks GSK to revise label of 2 asthma drugs

06/2/2010 | American City Business Journals · Reuters

The FDA ordered GlaxoSmithKline to change the warning label of asthma drugs Serevent and Advair. The long-acting beta-agonists have been shown to worsen asthma symptoms and result in hospitalization or death when used as a stand-alone treatment, according to the agency.

View Full Article in:

American City Business Journals · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ